Phase I and Pharmacological Study of Vinblastine

long-term venous access catheters has made prolonged infusion of vinblastine and ... 3The abbreviations used are: CVI, continuous vinblastine infusion...

0 downloads 0 Views 854KB Size

Recommend Documents

Departments of Medicine [J. L, A. T. H.. W. D. B., C. J.. .... abbreviations used are: ..... ftn. QJ . ÖU. uÜ 60 i. 40. 5 et. 20 • "' •IO •121. 16)- •141. 131.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008;7(9):2955-66. 44.

Mar 15, 2008 - cycle of therapy was 805/ul and the median platelet nadir was 48,000/ul. Other toxic .... This was achieved using a Waters model 510 pump and ...

Jul 15, 1995 - Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse. Antibody ... V. V., D. B., H. W., G. H.¡,Laboratory Medicine ¡H.F.], and Clinical Immunology and Biological Therapy [J. L M.],. The University of ....

Jan 15, 1994 - Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor .... to the aqueous insolubility of the closed-ring CPT lactone (1-7). ... O2CH 3. SN-38. Fig. 1. Structures of CPT-11 and SN-38. To date, phase I and II trials o

control. Clinical Pharmacological Studies. The pharmacokinetic behavior of. IDR was examined using a HPLC method adapted from that of Peng. 2990. Research. ... Compounds were de tected by fluorescence, using excitation and emission wavelengths of. 47

(254-S; NSC 37510ID) Administered by 5-Day Continuous Intravenous ..... macodynamics was calculated by the method of simple least squares of .... crease in total plasma platinum concentration between the early and later stages of drug administration.

them, to break down all of the components of the ECM, includ- ing the basement membrane (1). ... novel synthetic hydroxamic acid derivative (Fig. 1) able to .... (free base). 1913 ..... We wish to thank Drs. T. S. Ganesan and N. Dobbs (Imperial.

At the 560 mg/m2/day dose level, the mean percentage of .... patients with advanced solid malignancies; (b) determine the ... gational agents in the previous 4 weeks; (g) no nitrosoureas or ... local reactions were not considered in altering the incr

(Milford,. MA) as well as a Spectroflow. 980 programmable fluorescence detector. (Kratos. Division, ...... E. M., Pajak, T. F., and Bateman,. J. R. Adriamycin given.

Oct 13, 2006 - the adaptation and evaluation of the SFP10–14 ... Twenty-one percent of pupils ... 15–19 years are 16 times more likely to die than those of a ...

liters/h/m2 (n = 6; P < 0.002), denoting a departure from linear pharma- cokinetic behavior. The rather low steady ... ~To whom requests for reprints should be addressed, at the Laboratory of Pharma ceutical Chemistry, National ...... As anticipated

would experience grade 3 or 4 toxicity, and thus to define a dose suitable for broad phase II evaluation. ...... (D-19466; lobaplatin) admin istered daily for 5 days.

May 15, 2008 - hamster, and human cells to rBBX-01 (EC50 assay .... avastin; Gem/Dox, generic gemcitabine + pegylated liposomal doxorubicin; HKI-272, ...

Departments of Pediatric Hematology/Oncology, State University of. New York Upstate Medical University, .... Downloaded from ..... Neuro-Oncology, 4: 102–108, 2002. 5. .... Bernstein, M. L. WR-2721 (amifostine) infusion in patients with Ew-.

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

Oct 15, 2008 - Doxorubicin and trabectedin pharmacokinetics were not altered .... hematologic drug-related effects, and creatinine phosphokinase eleva-.

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

Dec 15, 2005 - Anthony W.Tolcher,1and Eric K. Rowinsky1. Abstract Purpose:To ...... Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ,. Bertram JS, Kowalski D.

Abstract. Purpose: VNP40101M is a novel sulfonylhydrazine al- kylating agent with broad antitumor activity in animal mod- els. As alkylating agents are ...

treatment of multiple myeloma, ovarian cancer, breast cancer, and neuroblastoma (3–5). .... ferases, -glutamyl-aminotransferase, alkaline phosphatase, and.